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regarding the manuscript: “Pattern of and
reason for postoperative residual disease in
patients with advanced ovarian cancer
following upfront radical debulking surgery”We thank Fagotti et al. for their interest in our paper describing the
patterns and sites of residual disease (RD) in patients with advanced
ovarian cancer who have undergone primary debulking surgery (PDS)
(Heitz et al., 2016) in an expert referral center. The colleagues compare
their own datawith ours even though the patients populations are quite
different with all incoming patients being analyzed in our series as op-
posed to only pre-selected patient cohorts reported in the Rome series.
Nevertheless, we appreciate and acknowledge that their continuous
surgical training led to an improvement of their complete resection
rates and overall surgical quality over the last years.
Fagotti et al. focus their discussion mainly around selection criteria
for ideal treatment strategies in patients with advanced ovarian cancer.
This was however not the main purpose of our analysis. Our aimwas to
identify and describe the patterns and sites of residual disease in pa-
tients operated in centers where not the skill of the surgical team is
the limit but rather the anatomical and tumor-biological factors.We de-
scribed the outcome of all incoming patients providing all associated in-
formation unbiased and without any preselection. Moreover, the
interpretation that we reported 30.3% of patients being not suitable
for PDS is inaccurate. Fagotti et al. added together all patients who did
not have primary surgery and those who underwent PDS with large re-
sidual disease. They missed the statement that half of the 161 patients
who did not undergo PDS was due to the reason of having already
started neoadjuvant therapy in centers elsewhere. Obviously, we were
not involved in the initial decision making process whether or not
these patients could have been candidates for PDS. As stated, the rate
of patients deemed not suitable for PDS in the cohort of patients that
have started treatment in our center was only 10.9%. In fact, PDS was
retrospectively not the best choice in 8.5% of the patients due to
RD N 1 cm – a pretty low rate compared with other series. Nevertheless,
this was sufﬁcient motivation for us to further deﬁne selection criteria
for PDS without withholding a high chance for (curative) complete re-
section (ongoing protocol AGO-OVAR 19). Laparoscopy as selection
aid had been shown to be beneﬁcial in Rome when complete resection
rates were much lower and comparable to ours at the beginning of our
learning curve (Harter et al., 2011). However, even with laparoscopy
complete resection rates were still lower than in our center without
pre-selection – and the same accounted for the cited SCORPION trial
in which 13.7% of patients were excluded before randomization due to
suspected inoperable disease but still 9.0% and 9.6% in the PDS and in-
terval debulking groups, respectively, were left with RD N 1 cm
(Fagotti et al., 2016).DOIs of original article: http://dx.doi.org/10.1016/j.gore.2016.11.003,
http://dx.doi.org/10.1016/j.ygyno.2016.03.015.
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were obviously misunderstood. Our group reported a slightly higher
surgical impact of AWM (Heitz et al., 2010) but we did not postulate
any negative impact on survival (Ataseven et al., 2016a). In contrast,
we even advocated modifying the FIGO classiﬁcation, as we showed
that prognosis of patients with stage IVB due to AWM is superior com-
pared to all other FIGO IV locations (Ataseven et al., 2016b).
Finally, we disagree with Fagotti et al. regarding the statement about
upfront chemotherapy and interval debulking (NACT-IDS), that “.. The fu-
ture is designing small clinical trials for groups of patients, inserted into a
clear clinical scenario, showing speciﬁcmarkers of the disease”. As report-
ed in our actual (Heitz et al., 2016) and previous (Vergote et al., 2010) pa-
pers, we doubt that the design of the EORTC- (Vergote et al., 2010) and
the CHORUS-trials (Kehoe et al., 2015) could reliably test the hypothesis,
that upfront chemotherapy followed by interval debulking is non-inferior
or even superior to PDS. We rather interpret these trials as proof that
NACT-IDS is non-inferior to primary surgery in a setting of low surgical ef-
fort and limited success. Therefore, the AGO-Trial on Radical Upfront Sur-
gery in AdvancedOvarian Cancer (TRUST; NCT#02828618)was designed
to compare maximum effort PDS performed in centers with proven high
surgical qualitywith equallymaximal effort NACT-IDS,more rigorously as
the ﬁrst randomized phase III trials. A large cohort of patients is needed to
prove the hypothesis of an overall survival beneﬁt of patients undergoing
PDS compared to patients undergoing NACT-IDS.We believe that surgical
questions should be addressed only by experienced surgeons, therefore,
the TRUST trial only includes centerswith externally proven surgical skills
and audited by experienced surgeons.
Not a single chemotherapy trial would ever have been accepted if
the dose intensity or protocol completion rate achieved had been at
such low ranges similar to the low complete resection rates described
in the NACT-IDS trials.
In any case, the fate of a patient should not dependon throughwhich
door she enters – Rome or Essen or elsewhere. Rather robust quality im-
provement criteria and strategies should be implemented in all centers
performing this kind of treatments. Fagotti et al. have their merits by
assessing the value of laparoscopy in this setting, our focus lies rather
on other areas but nevertheless each of us has a small piece to contrib-
ute to the bigger picture.
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